ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome

R. Rattanavich, M. De Vera, T. Hoang, R. Villicana

Loma Linda University, Transplant Institute, San Bernadino, CA

Meeting: 2020 American Transplant Congress

Abstract number: 168

Keywords: Antibodies, Hepatitis C, Kidney, Kidney transplantation

Session Information

Session Name: Donor Derived Infections

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT – donors have seroconverted but its impact on renal allograft outcome has rarely been reported. We studied renal allograft outcomes in HCV AB+/NAT – donor kidney transplant patients with hepatitis C antibody seroconversion and without seroconversion.

*Methods: A retrospective review was conducted in 49 HCV NAT negative patients who received kidney transplant HCV Ab+/NAT – donors from 01/2017-11/2018. Patients received thymoglobulin induction and maintenance with tacrolimus, mycophenolate and prednisone. Patients were analyzed by dividing into 2 groups, seroconversion and no seroconversion group. Seroconversion was defined by patients who have HCV antibody negative converted to positive and no seroconversion group who were negative and remain negative after transplant. No patients in either group became viremic. Data were collected up to 12 months. Statistical significance was based on t test for continuous variables and chi square analyses for categorical variables.

*Results: We found that patients with hepatitis C antibody seroconversion received higher KDPI score kidneys and patients without seroconversion group had higher cPRA. Both groups of patient had no significant differences in serum Cr, eGFR, proteinuria, acute rejection, graft survival and patient survival rates at 12 months.

*Conclusions: 51% patients with Hepatitis C antibody positive/NAT negative donors have seroconverted but no significant difference was noted when compared to patients without seroconversion. Larger studies with longer follow up are required to confirm these findings

Patient Demographics
Seroconversion(n = 25) No Seroconversion(n=24) P-Value
Age (years) 59.64 ±10.15 55.66 ±11.8 0.21

African American/

Others

0/25 (0)
3/24 (12.5%)
0.69
cPRA (%) 1.08 ±3.39 19.83 ±32.30 0.01
Cold Ischemic Time 1220.44 ±321.10 1312.75±523.94 0.46
Donation after Circulatory death (DCD) 7/25 (28%) 7/24 (29.17%) 0.93
KDPI score (%) 76.48 ±19.91 63.83±22.07 0.04
Outcome
Seroconversion No Seroconversion P-value
DGF (%) 11/25 (44%) 9/24 (37.5%) 0.65
Cr 3 mo 1.31 ±0.45 1.16 ± 0.87 0.23
Cr 6 mo 1.39 ±0.56 1.20 ± 0.37 0.17
Cr 12 mo 1.28 ±0.49 1.28 ± 0.41 0.95
eGFR 3 mo 55.92 ±19.21 58.08 ± 21.36 0.71
eGFR6 mo 54.04 ± 19.78 63.04 ± 21.71 0.14
eGFR 12 mo 59.50 ± 21.34 58.45 ± 19.84 0.87
outcome
Seroconversion No Seroconversion P-value
Urine Protein/Cr ratio 3 mo 0.49 ± 0.76 0.23 ± 0.20 0.15
6 mo 0.49 ±1.10 0.35 ± 0.44 0.59
12 mo 0.40 ±0.93 0.26 ± 0.28 0.53
Positive DSA within 12 Mo 3/25 (12%) 8/24 (33.3%) 0.47
12 mo Acute rejection rate (%) 0/25 (0) 0/24 (0) 0
12 mo graft survival 24/25 (96%) 23/24 (95.8%) 0.31
12 mo patient survival (%) 24/25 (96%) 24/24 (100%) 0.33
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Rattanavich R, Vera MDe, Hoang T, Villicana R. Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/hepatitis-c-antibody-seroconversion-in-kidney-transplant-patients-from-hcv-antibody-positive-nat-negative-donors-does-not-deteriorate-renal-allograft-outcome/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences